Neoadjuvant chemotherpy with gemcitabine and oral S-1for pancreatic cancer

Neoadjuvant chemotherpy with gemcitabine and oral S-1for pancreatic cancer - NAC with GEM+S-1

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011064

Enrollment

Registered

2013-07-01

Start date

2009-07-10

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable pancreatic cancer

Interventions

preoperative chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1) Patients with anti-cancer agent administration in history past 2) Active another cancer 3) Severe complications 4) Patients with interstitial pneumonia or pulmonary fibrosis 5) Active infection 6) Pregnant woman 7) Severe mental disorder 8) Others

Design outcomes

Primary

Measure	Time frame
Determination of the recommended dose	—

Countries

Japan

Contacts

Public ContactHidehiro Tajima

Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery

hidetaji@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026